首页> 外文期刊>Human Reproduction >Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study.
【24h】

Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study.

机译:非肥胖年轻多囊卵巢综合征不育妇女在辅助生殖技术之前和期间使用二甲双胍:一项前瞻性,随机,双盲,多中心研究。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: To study the effect of metformin before and during assisted reproductive technology (ART) on the clinical pregnancy rate (CPR) in non-obese women with polycystic ovary syndrome (PCOS). METHODS: A multi-centre, prospective, randomized, double-blind study was conducted in eight IVF clinics in four Nordic countries. We enrolled 150 PCOS women with a body mass index <28 kg/m(2), and treated them with 2000 mg/day metformin or identical placebo tablets for >/= 12 weeks prior to and during long protocol IVF or ICSI and until the day of pregnancy testing. The primary outcome measure was CPR. Secondary outcome measures included spontaneous pregnancy rates during the pretreatment period, and the live birth rate (LBR). RESULTS: Among IVF treated women (n = 112), biochemical pregnancy rates were identical in both groups (42.9%), and there were no significant differences in the metformin versus the placebo group in CPR [39.3 versus 30.4%; 95% confidence interval (CI): -8.6 to 26.5]. The LBR was 37.5 versus 28.6% (95% CI: -8.4 to 26.3). However, prior to IVF there were 15 (20.3%) spontaneous pregnancies in the metformin group and eight (10.7%) in the placebo group (95% CI: -1.9 to 21.1; P = 0.1047). According to intention to treat analyses (n = 149); significantly higher overall CPR were observed in the metformin versus placebo group (50.0 versus 33.3%; 95% CI: -1.1 to 32.3; P = 0.0391). LBR was also significantly higher with use of metformin versus placebo (48.6 versus 32.0; 95% CI: 1.1 to 32.2; P = 0.0383). No major unexpected safety issues or multiple births were reported. More gastrointestinal side effects occurred in the metformin group (41 versus 12%; 95% CI: 0.15 to 0.42; P < 0.001). CONCLUSIONS: Metformin treatment for 12 weeks before and during IVF or ICSI in non-obese women with PCOS significantly increases pregnancy and LBRs compared with placebo. However, there was no effect on the outcome of ART per se. Trial registration: ClinicalTrials.gov Identifier: NCT00159575.
机译:背景:研究辅助生殖技术(ART)之前和期间的二甲双胍对非肥胖多囊卵巢综合征(PCOS)妇女的临床妊娠率(CPR)的影响。方法:在北欧的四个国家的八个试管婴儿诊所进行了多中心,前瞻性,随机,双盲研究。我们招募了150名体重指数<28 kg / m(2)的PCOS妇女,并在长程IVF或ICSI之前和期间用2000 mg /天的二甲双胍或相同的安慰剂片剂治疗了> / = 12周,直到怀孕测试的一天。主要结局指标为心肺复苏。次要结局指标包括预处理期间的自然怀孕率和活产率(LBR)。结果:在接受IVF治疗的妇女(112例)中,两组的生化妊娠率相同(42.9%),二甲双胍和安慰剂组的心肺复苏率无显着差异[39.3%对30.4%; 95%置信区间(CI):-8.6至26.5]。 LBR为37.5,而前者为28.6%(95%CI:-8.4至26.3)。但是,在进行IVF之前,二甲双胍组有15例(20.3%)自发性妊娠,安慰剂组有8例(10.7%)(95%CI:-1.9至21.1; P = 0.1047)。根据意图进行分析(n = 149);与安慰剂组相比,二甲双胍组的总CPR显着提高(50.0对33.3%; 95%CI:-1.1至32.3; P = 0.0391)。与安慰剂相比,使用二甲双胍的LBR值也显着更高(48.6 vs 32.0; 95%CI:1.1至32.2; P = 0.0383)。没有重大的意外安全问题或多胎的报道。二甲双胍组发生更多的胃肠道副作用(41%vs 12%; 95%CI:0.15至0.42; P <0.001)。结论:与安慰剂相比,在非肥胖的PCOS妇女中,IVF或ICSI之前和期间进行二甲双胍治疗12周显着增加了妊娠和LBRs。然而,对ART本身的结果没有影响。试验注册:ClinicalTrials.gov标识符:NCT00159575。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号